Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients

Abstract excerpt

Tacrolimus, a calcineurin inhibitor, is widely used to prevent allograft rejection in kidney transplant recipients. Its metabolism is predominantly mediated by the cytochrome P450 3A5 (CYP3A5) enzyme, and single nucleotide variants (SNVs) within intron 3 of the CYP3A5 gene are strongly associated with interindividual variability in enzyme expression and activity. These SNVs can generate a cryptic splice site,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Organ Transplantation Techniques and Outcomes
• Share to Pharmacological Effects and Toxicity Studies
• Share to Renal Transplantation Outcomes and Treatments